3 gene ther­a­py com­pa­nies se­cure VC mon­ey; No­valis clos­es near­ly $30 mil­lion fund

A Eu­ro­pean life sci­ences VC firm will in­vest in three more star­tups spe­cial­iz­ing in rare ge­net­ic dis­eases as a part of its Sofinno­va Telethon Fund, the com­pa­ny an­nounced Wednes­day.

AA­Vant­garde Bio, Alia Ther­a­peu­tics and Borea Ther­a­peu­tics will re­ceive seed fund­ing worth a to­tal of $7.1 mil­lion. The fund is ded­i­cat­ed to biotechs in Italy, and led by Lu­cia Fac­cio and Pao­la Pozzi, Part­ners at Sofinno­va Part­ners.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER